• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc. (Amendment)

    2/9/24 9:16:05 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.17 IONIS PHARMACEUTICALS INC COMMON STOCK Cusip #462222100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #462222100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 21,519,114 Item 6: 0 Item 7: 21,520,872 Item 8: 0 Item 9: 21,520,872 Item 11: 15.000% Item 12: HC Cusip #462222100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 21,520,872 Item 8: 0 Item 9: 21,520,872 Item 11: 15.000% Item 12: IN Item 1(a). Name of Issuer: IONIS PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 2855 GAZELLE COURT Carlsbad, CA 92010 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 462222100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 21,520,872 (b) Percent of Class: 15.000% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 21,520,872 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of IONIS PHARMACEUTICALS INC. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of IONIS PHARMACEUTICALS INC, amounted to 9,268,403 shares or 6.460% of the total outstanding COMMON STOCK at December 29, 2023. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of IONIS PHARMACEUTICALS INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $IONS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    9/26/2025$65.00Sell → Neutral
    Goldman
    9/3/2025$70.00Market Perform → Outperform
    BMO Capital Markets
    7/31/2025$62.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$57.00Equal Weight → Overweight
    Barclays
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    8/2/2024$67.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/24/2024$53.00 → $62.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ionis Pharma upgraded by Goldman with a new price target

    Goldman upgraded Ionis Pharma from Sell to Neutral and set a new price target of $65.00

    9/26/25 8:00:14 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $70.00

    9/3/25 8:16:13 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Ionis Pharma from Equal-Weight to Overweight and set a new price target of $62.00

    7/31/25 7:07:33 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA. The letter did not cite any deficiencies in the clinical data of the high dose regimen. The FDA provided options for resolution, and Biogen is planning to resubmit the application promptly based upon readily availabl

    9/23/25 4:30:00 PM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

    – First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition – – NDA submission planned in Q1 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization on the primary endpoint of gait speed as assessed by the 10-Meter Walk Test (10MWT) compared to control at week

    9/22/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

    Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The approval follows the positive opinion of the Committee for Medicinal Products for Human Use. The approval is based on positive data from the Phase 3 Balance study, in which TRYNGOLZA 80 mg demonstrated a statistically significant reduction in fasting triglyceride levels at six months that was sustained through 12 months. Additionally, TRYNGOLZA demonstrated a substantial and clinically meaningful reduction in acute pancreati

    9/19/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    SEC Filings

    View All

    SEC Form 144 filed by Ionis Pharmaceuticals Inc.

    144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    9/30/25 4:49:22 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    9/22/25 7:05:51 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ionis Pharmaceuticals Inc.

    144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    9/3/25 4:37:28 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    5/2/25 4:38:26 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    12/26/24 4:57:52 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Financials

    Live finance-specific insights

    View All

    Ionis reports second quarter 2025 financial results and highlights progress on key programs

    - TRYNGOLZATM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis' second independent launch - - Phase 3 data from the pivotal CORE and CORE2 studies in severe hypertriglyceridemia (sHTG) expected in September 2025 - - Increasing 2025 financial guidance based on strong performance and improved outlook - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2025. "During the second quarter, we continued to build momentum across our business," said Brett P. Monia, Ph.D., chief execu

    7/30/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

    Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

    6/25/25 7:30:37 AM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ionis reports first quarter 2025 financial results

    - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

    4/30/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 1:28:29 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

    SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/8/24 10:52:38 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Leadership Updates

    Live Leadership Updates

    View All

    Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products

    Ionis announces the appointment of Michael Yang to Board of Directors

    CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

    12/14/23 4:05:00 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP CLO & General Counsel O'Neil Patrick R. exercised 1,700 shares at a strike of $56.78 and sold $109,787 worth of shares (1,700 units at $64.58) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    9/16/25 4:56:38 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Business Officer Baroldi Joseph exercised 11,950 shares at a strike of $31.80 and sold $742,838 worth of shares (11,950 units at $62.16) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    9/11/25 5:05:07 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP CLO & General Counsel O'Neil Patrick R. exercised 21,000 shares at a strike of $60.69 and sold $1,355,661 worth of shares (21,000 units at $64.56) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    9/11/25 5:04:46 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care